Cumberland Pharmaceuticals, Inc. 是一家专业制药公司,专注于品牌处方药品的收购、开发和商业化。公司总部位于田纳西州纳什维尔,目前拥有91名全职员工。公司于2009年8月11日上市。该公司致力于品牌处方药品的收购、开发和商业化。其品牌组合包括:Acetadote(乙酰半胱氨酸)注射剂,用于对乙酰氨基酚中毒的治疗;Caldolor(布洛芬)注射剂,用于治疗疼痛和发烧;Kristalose(乳果糖)口服溶液,一种处方泻药,用于治疗便秘;Sancuso(格拉司琼)透皮贴剂,用于预防接受某些类型化疗的患者的恶心和呕吐;Vaprisol(考尼伐坦)注射剂,用于提高因等容或高容性低钠血症住院患者的血清钠水平;以及Vibativ(特拉万星)注射剂,用于治疗某些严重的细菌感染,包括医院获得性和呼吸机相关性细菌性肺炎,以及复杂的皮肤及皮肤结构感染。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CPIX. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CPIX is a Sell candidate.
CPIX stock price ended at $3.85 on 星期二, after rising 0.00%
On the latest trading day Feb 10, 2026, the stock price of CPIX rose by 0.00%, climbing from $3.94 to $3.85. Throughout the session, the stock experienced a volatility of 5.32%, with prices fluctuating between a daily low of $3.76 and a high of $3.96. Alongside this price increase, trading volume also rose by 104 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 93.3K shares were traded, amounting to a market value of approximately $57.5M.